<p><strong>INFLUENCE OF MUSHROOM GANODERMA LUCIDUM (CURT.: FR.) P. KARST. ON THE HUMORAL IMMUNE RESPONSE IN MICE LINE CBA / Ca WITH SECONDARY IMMUNODEFICIENCY.</strong></p><p><strong>V.T. Pidchenko*, I.V. Nizhenkovska*, N.G. Bychkova*, N.A. Bisko**, A.Y. Rodnichenko***</strong></p><p>*Bogomolets National medical university, Kyiv</p><p>**M.G. Kholodny Institute of Botany NASU, Kyiv</p><p>***The State Institute of Genetic and Regenerative MedicineNAMSUkraine, Kyiv</p><p> </p><p><strong>Summary:</strong> The article shows the results of the investigation of the influence of biomass powder of mushroom Ganoderma lucidum on the humoral immune response in mice line CBA / Ca in terms of the simulated secondary immunodeficiency. To simulate the immunodeficiency was used the immunosuppressant cyclophosphamide, which was administered once a dose of 150 mg / kg, intraperitoneally, the first day of the experiment. Results of the study show that the application of Ganoderma Lucidum biomass powder in mice line CBA / Ca with induced immune deficiency, causes a significant increase in the number of antibody-producing cells in the spleen and antibody levels in serum.</p><p><strong> </strong></p><p><strong>Key words:</strong> Ganoderma lucidum, humoral immune response, cyclophosphamide, immunodeficiency.</p><p><strong> </strong></p><p><strong>Introduction.</strong> Searching and development of remedies of natural origin is an actual problem today. In recent decades, basidiomycetes and biologically active substances extracted from them, attracted attention of scientists in Asia andNorth America. Ganoderma lucidum, a native biosidiomycetous fungus, has been used inChina,Japan andKorea to prevent and treat bronchitis, chronic hepatitis, hypertension, atherosclerosis, tumor growth and immunological disorders for over 2000 years. The influence of biomass powder of mushroom Ganoderma lucidum, grown by submerged cultivation, at various immunity in immunodeficient conditions is not studied. Therefore the aim of our study was to determine the influence of biomass powder of mushroom Ganoderma lucidum on humoral immune response in mice with secondary immunodeficiency in vivo.</p><p><strong> </strong></p><p><strong>Methods.</strong> The biomass of mushroom Ganoderma lucidum was grown by submerged cultivation. To simulate the immunodeficiency was used the immunosuppressant cyclophosphamide, which was administered once a dose of 150 mg / kg, intraperitoneally, the first day of the experiment. The number of antibody-producing cells in the spleen and antibody levels in serum were discovered. Statistical analysis of the results was performed using Student`s t-test.<strong></strong></p><p><strong> </strong></p><p><strong>Results and discussion.</strong></p><p>The introduction of biomass powder of mushroom Ganoderma lucidum for 10 days to mice line CBA / Ca with secondary experimental immunodeficiency causes a significant increase in the number of cells in femur.</p><p>The recovery of thymus weight, relative thymus weight, thymus settlement index and number of lymphoid cells in the organ to the level of data in a group of control mice after the administration of biomass powder was not found.</p><p>The introduction of biomass powder of mushroom Ganoderma lucidum to mice line CBA / Ca with secondary experimental immunodeficiency causes a significant increase in the relative number of antibody-producing cells in the spleen in 2 times, the absolute number of antibody-producing cells in 2,1 times compared with the group of mice treated with cyclophosphamide. The antibody levels increase in 6,7 times (hemolysin titer) and 2,4 times (hemagglutinin titer).</p><p><strong>Conclusions.</strong> Thus, the results of the study show that the introduction of biomass powder fungus Ganoderma lucidum to mice line CBA / Ca with secondary experimental immunodeficiency causes a significant increase in the number of antibody-producing cells in the spleen and antibody levels in serum, which may indicate the immunomodulatory effect of biomass powder of fungus Ganoderma lucidum on humoral immune response.</p>
Read full abstract